Seguridad de las terapias biológicas: nuevos datos de BIOBADASER

Comité Científico de BIOBADASER. BIOBADASER: Registro español de acontecimientos adversos de terapias biológicas en enfermedades reumáticas. Rev Esp Reumatol. 2002;29:292–99. Dixon, 2010, EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology, Ann Rheum Dis., 69, 1596, 10.1136/ard.2009.125526 García-Doval, 2010, Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists, Ann Rheum Dis., 69, 1751, 10.1136/ard.2009.125658 Peña-Sagredo, 2008, Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience, Clin Exp Rheumatol., 26, 854 Peña-Sagredo, 2009, Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy, Clin Exp Rheumatol., 27, 920 Gomez-Reino, 2003, Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report, Arthritis Rheum., 48, 2122, 10.1002/art.11137 Carmona, 2005, Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists, Arthritis Rheum., 52, 1766, 10.1002/art.21043 Gomez-Reino, 2007, Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection, Arthritis Rheum., 57, 756, 10.1002/art.22768 Carmona, 2011, Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0, Rheumatology (Oxford)., 50, 85, 10.1093/rheumatology/keq207 Jacobsson, 2007, Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis, Ann Rheum Dis., 66, 670, 10.1136/ard.2006.062497 Lunt, 2010, Symmons D and Hyrich K on behalf of the BSR Biologics Register No evidence of association between anti-TNF treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register, Arthritis & Rheumatism, 62, 3145, 10.1002/art.27660 Carmona, 2007, All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists, Ann Rheum Dis., 66, 880, 10.1136/ard.2006.067660 Pérez-Zafrilla, 2008, Reacciones adversas relacionadas con la administración de inhibidores del TNF, Análisis de un registro de terapias biológicas. Reumatol Clin., 4, 90 Harrison, 2009, British Society for Rheumatology Biologics Register Control Centre Consortium; BSRBR, Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor a therapy: results from the British Society for Rheumatology Biologics Register Ann Rheum Dis., 68, 209 Collamer, 2010, Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis, Semin Arthritis Rheum., 40, 233, 10.1016/j.semarthrit.2010.04.003 Bernatsky, 2010, Demyelinating events in rheumatoid arthritis after drug exposures, Ann Rheum Dis., 69, 1691, 10.1136/ard.2009.111500 Fernández-Espartero, 2010, Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review, Semin Arthritis Rheum., 40, 330, 10.1016/j.semarthrit.2010.06.004 Listing, 2008, Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?, Arthritis Rheum., 58, 667, 10.1002/art.23281 Dixon, 2007, Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register, Arthritis Rheum., 56, 2905, 10.1002/art.22809 Khasnis, 2010, Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk, Semin Arthritis Rheum., 40, 147, 10.1016/j.semarthrit.2009.09.001 Pollono, 2010, A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis, Clin Rheumatol., 29, 947, 10.1007/s10067-010-1405-7 Vinet, 2009, Biologic therapy and pregnancy outcomes in women with rheumatic diseases, Arthritis & Rheumatism (Arthritis Care & Research), 61, 587, 10.1002/art.24462